Overall, the distinction between ligand neutralization and receptor blockade represents a therapeutic paradigm shift in RA, providing therapeutic options beyond TNF-α, IL-6, and B cell-directed biologics for patients unresponsive to current treatments. Here, TNF is linked to rheumatoid arthritis.